A chemical tool for improved culture of human pluripotent stem cells

Laurence Silpa¹, Maximilian Schuessler¹, Gu Liu², Marcus Olivecrona², Lucia Groizard-Payeras², Elizabeth Couper³, Carole J. R. Bataille², Mark Stevenson⁴, Len W. Seymour⁴, Stephen G. Davies², William S. James³, Sally A. Cowley^{3*}, Angela J. Russell^{1,2*}.

¹Department of Pharmacology, University of Oxford, Mansfield Rd, Oxford OX1 3QT, UK; ²Department of Chemistry, Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, OX1 3TA, Oxford, UK; ³James Martin Stem Cell Facility, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK; ⁴Department of Oncology, Old Road Campus Research Building, University of Oxford, Roosevelt Drive Oxford, OX3 7DQ, UK

Abstract

The large-scale and cost-effective production of quality-controlled human pluripotent stem cells (hPSC) for use in cell therapy and drug discovery requires chemically-defined xenobiotic-free culture systems that enable easy and homogeneous expansion of pluripotent cells. Through phenotypic screening, we have identified a small molecule, OXS8360 (an optimized derivative of (-)-Indolactam V ((-)-ILV)), that stably disrupts hPSC cell-cell contacts. Proliferation of hPSC in OXS8360 is normal, as are pluripotency signatures, directed differentiation to hallmark lineages and karyotype over extended passaging. In 3D culture, OXS8360-treated hPSC form smaller, more uniform aggregates, that are easier to dissociate, greatly facilitating expansion. The mode of action of OXS8360 involves disruption of the localisation of the cell-cell adhesion molecule E-cadherin, via activation of unconventional Protein Kinase C isoforms. OXS8360 media supplementation is therefore able to yield more uniform, disaggregated 2D and 3D hPSC cultures, providing the hPSC field with an affordable tool to improve hPSC quality and scalability.

Introduction.

Human pluripotent stem cells (hPSC) have the unique properties of indefinite self-renewal and the ability to differentiate into representatives of the three germ layers¹. However, a fundamental requirement needed to exploit the full potential of hPSC, in both research and medicine, is the ability to produce large numbers of

cells of consistent quality and in a cost effective manner. In addition, the application of hPSC also requires ease of use, and good manufacturing practice (GMP) compatibility, without compromising pluripotency or increasing heterogeneity in the culture². While hPSC are most commonly grown in chemically defined media, such as mTeSR1TM³ or E8⁴, the main challenge encountered in traditional 2D culture methods is the limited quantities in which hPSC can be produced for experimental and therapeutic application. Zweigerdt *et al.*⁵ have shown that at least 2×10^9 differentiated cells of the representative lineage would be necessary to treat one individual in the case of heart repair or β -cell replacement in type 1 diabetes, which requires about 500 densely grown 10-cm dishes and complex automation. One strategy for overcoming these difficulties is to develop 3D suspension culture methods allowing more reliable, simple, cost-effective and industrial-scale production of hPSC versus 2D systems. Free-floating 3D cultures (e.g. suspension culture in bioreactors) are expected to meet the high demand for cells needed for such applications. However, this approach can invoke problems with cell aggregation. Cells in the centre of these aggregates are generally underexposed to the medium, resulting in variable growth rates, apoptosis, uncontrolled differentiation and an eventual increase in heterogeneity⁶. Others have also explored the use of mechanical agitation (limited by shearing force), microcarriers, micropatterning and thermoreversible hydrogels^{7, 8}. Despite their contribution to the field, each has its own limitations and struggle either to support rapid expansion or to prevent the formation of heterogeneous cell aggregates, leading to loss of pluripotency at higher cell densities^{2, 8}. Chemical approaches to disrupt cell-cell contact in hPSC while maintaining pluripotency are an innovative approach to address this issue. A similar strategy has been previously described for mouse embryonic stem cells (mESC)^{9, 10}. Here, we describe the novel use of a small molecule that reduces cell-cell adhesion, allowing the formation of smaller and more homogeneous hPSC aggregates while maintaining both pluripotency and viability, thereby improving scalability.

Results.

(-)-ILV and OXS8360 induce iPSC spreading in 2D cultures.

Disruption of cell-cell junctions is a requirement for epithelial cells to scatter⁹. With this in mind, a phenotypic screening assay was developed to identify small molecules causing hPSC colony disruption on the OX1-18 cell

line¹¹ in the first instance (Table S1). This identified the natural compound (-)-ILV (Fig. 1a), which allowed cells to separate from their neighbours in a concentration-dependent manner, with a minimal effective concentration of 1 μ M (Fig. 1b). However, as (-)-ILV exhibited a reduction in cell viability over time (Fig. S1), an analysis of structural analogues of (-)-ILV was undertaken. One analogue, OXS8360 (Fig. 1a), induced iPSC cell scattering at 1 μ M while maintaining high viability, as assessed by acridine orange. iPSC were cultured in the presence of (-)-ILV or OXS8360 and imaged after 3, 12 and 24h of treatment (Fig. 1b). Morphological changes were observable within 3h post treatment, with particularly pronounced separation of cells on colony peripheries, indicating the rapid effect of OXS8360. Colony disruption was more evident at 12h and reached a completely non-colony-based phenotype by 24h. Live imaging of OXS8360-treated iPSC also showed a dynamically spreading phenotypic effect over 5 hours versus untreated cells (Video, S.I). Additionally, three genetically distinct healthy control donor iPSC lines (SFC840-03-06, SFC85403-02, and SFC856-03-04¹²) (Table S1) treated with either (-)-ILV or OXS8360 showed the same phenotypic effect, demonstrating the robustness of the effect (Fig. S2). Finally, the karyotypes of all four iPSC cell lines remained stable over 10 passages of OXS8360-treatment (Fig. S3).

Next, the reversibility of (-)-ILV and OXS8360-induced morphological changes was assessed (experimental timeline schematically presented in Fig. 1c). 24h after plating (in medium containing Rho-kinase inhibitor Y27632 to prevent apoptosis during single cell passaging), iPSC started to form early colonies. Removal of Rho-kinase inhibitor and subsequent treatment with 1 μ M (-)-ILV or OXS8360 showed colony disruption 24h later. Finally, colony-based morphology was restored 24h after a compound-free medium change (Fig. 1c).

As (-)-ILV or OXS8360 treatment induced iPSC scattering, the resultant changes in cell morphology were quantified. Treatment with (-)-ILV or OXS8360 induced a significant reduction in cell density (nuclei/area) versus DMSO (3.5-fold and 2.7-fold, respectively). This was accompanied by a flattening of the phenotype, resulting in nuclei that were significantly greater in area and perimeter but significantly reduced in height (Fig. 1d). Geometric mean forward scatter (which reflects cell volume, obtained from flow cytometry datasets) showed no significant difference between OXS8360-treated and untreated iPSC (by comparison, human dermal fibroblasts (HDF) were significantly higher, Fig.1d), showing that overall cell volume was not

changed, just a transition to a more flattened phenotype. Staining of iPSC actin filaments with phalloidin-iFluor 488 revealed cytoskeleton remodelling upon (-)-ILV or OXS8360 treatment. Control iPSC were characterized by few but organized actin filaments at cell-cell contacts, whereas (-)-ILV or OXS8360-treated iPSC had a significant increase (5.8 and 3.5 fold, respectively) in phalloidin signal, with F-actin arranged as stress fibres, indicative of weak cell-cell junctions^{13, 14} (Fig. 1d and 1e). These results show that both (-)-ILV and OXS8360 induce colony disruption involving substantial actin rearrangement in 2D-cultured iPSC, and that this phenotype is reversible.

iPSC proliferate normally with OXS8360.

As we had noted that (-)-ILV was toxic to iPSC, we explored the mechanism of cell death, and determined the concentration that inhibits cell survival by 50% for each compound. Activity assays for caspase 3 and 7 in whole cell lysates from iPSC treated over 24 h with concentrations ranging from 0.1 to 100 μ M showed that (-)-ILV induced caspase 3 and 7 activation in a dose-dependent manner, with half maximal activity at 0.33 μ M (Fig. S4). Half maximal activity for OXS8360-treated cells was at 89.1 μ M, indicating much lower caspase induction. Flow cytometry for Annexin V-FITC and Propidium Iodide of (-)-ILV-treated cells showed that over 72h they shifted progressively from a population of healthy cells (Q4) to early apoptotic (Q3) and late apoptotic populations (Q2) (Fig. S5). These findings show that (-)-ILV exhibits high toxicity towards iPSC, therefore (-)-ILV was not used further, and only OXS8360 was taken forward for further studies.

To test whether iPSC proliferative ability would be affected following OXS8360 treatment, we examined expression of Ki-67, a protein that is present during all active phases of the cell cycle (G(1), S, G(2), and mitosis), but is absent from resting cells (G(0))¹⁵. Confocal imaging of untreated and OXS8360-treated iPSC for three passages revealed high levels of Ki-67 staining in both conditions (with HDF serving as a low-proliferating control) (Fig. 2a). Flow cytometry quantification of Ki-67-positive cells showed no significant difference between OXS8360 treated iPSC (99.4% $\pm$ 0.05; n=3), versus controls (99.0% $\pm$ 0.12; n=3), with HDF (12.3% $\pm$ 0.03, n=3) significantly lower than iPSC (Fig. 2b, 2c).

109 ***OXS8360-treated iPSC maintain pluripotent signatures.***

110 We next examined whether OXS8360 had any effect on the pluripotency signatures of iPSC treated over
111 multiple passages. Firstly, untreated cells or cells treated for 3 passages were similarly Nanog⁺/Tra-1-
112 60⁺/SSEA-3⁺/SSEA-4⁺ by flow cytometry (Fig. 3a), and negative for the mesenchymal surface marker CD44¹⁶.
113 Furthermore, immunocytochemical analysis of cells confirmed Tra-1-60 and Nanog expression (Fig. 3b). iPSC
114 treated with OXS8360 over 10 passages continued to express Tra-1-60 and Nanog, more consistently than
115 the untreated controls, in all four genetically distinct cell lines (Fig. S6). Therefore, the expression of
116 pluripotency markers in iPSC cultured with 1μM OXS8360 is stable over at least 10 passages.

117
118 Gene expression signatures can effectively report on the differentiation potential of hPSCs¹⁷, and ScoreCard,
119 a qRT-PCR-based assay that evaluates pluripotency and differentiation signatures, offers a valuable
120 quantitative approach for line-to-line comparison. Moreover, ScoreCard has been shown to be sensitive
121 enough to compare the functional pluripotency of samples in distinct culture conditions, making it an
122 appropriate genetic tool for our purpose¹⁸. Hence, Scorecard was used to test iPSC treated for three passages
123 with OXS8360, to assess self-renewal signatures and undirected differentiation to the three germline lineages
124 via embryoid bodies (EBs)^{19, 20} (imaged in Fig. S7). Both control DMSO and OXS8360-treated iPSC displayed
125 expected expression signatures representing pluripotency, ectodermal, mesodermal and endodermal
126 differentiation (Fig. 3c), expressed in an algorithm score against a reference dataset (Fig.3d), with consistent
127 positive scores for pluripotency and negative scores for the three differentiation signatures as
128 undifferentiated cells, and upregulated gene signatures for all three germ layers upon spontaneous
129 differentiation (Fig.3e, Ct values Table S2).

130

131 ***OXS8360-treated iPSC exhibit normal directed differentiation.***

132 We then assessed the capacity of iPSC treated with OXS8360 for three-passages to differentiate along defined
133 pathways. iPSC differentiated to mesoderm-derived, primitive macrophages (pMac)^{11, 21} displayed expected
134 morphology, including voluminous cytoplasm, membrane ruffles, and a proportion with an elongated
135 spindle-like form¹¹ (Fig.4a), together with characteristic macrophage cluster of differentiation (CD) markers

CD11b, CD14 and CD45 (Fig. 4b). Directed differentiation of iPSC treated for three passages with OXS8360 to a neuroectodermal lineage (cortical neuron progenitors)²², gave rise to neuronal rosettes on day 16, followed by neurons visible at day 25 (Fig. 4c), which expressed cortical neuron markers TUJ1 and PAX-6 (Fig. 4d). Together, these results show that OXS8360-treated iPSC are competent at directed differentiation to key mesodermal and neuroectodermal lineages.

3D culture of iPSC with OXS8360 enables formation of smaller aggregates.

To assess whether the scattering of OXS8360-treated iPSC in 2D culture would lead to improved 3D culture, iPSC were seeded in six-well low attachment plates at 0.5×10^6 cells per well (adapted from Zweigert *et al.*⁵) and cultured for 10 passages in suspension, subculturing every 4 days with or without OXS8360. 4 days after the 10th passage, untreated cells remained in large aggregates, whereas OXS8360 treated iPSC formed much smaller aggregates (Fig. 5a, Fig. S8). After 10 passages, Tra 1-60 and Nanog showed bimodal expression in the untreated cells, indicating a population of non-pluripotent cells, whereas OXS8360-treated cells retained a monomodal expression (Fig. 5b). Mean aggregate area was significantly smaller for OXS8360-treated ($p < 0.001$) versus untreated cultures (Fig. 5c). A three to six-fold expansion in seeded cells was observed during each passage for both conditions (Fig. S9). OXS8360-treated aggregates were much more easily dissociated to single cells as evidenced by significantly fewer residual cell clusters ($14.5\% \pm 1.15$, $n=3$, $p<0.001$) versus control cultures ($33\% \pm 1.15$, $n=3$) (Fig. 5d). Finally, the karyotype of iPSC treated with OXS8360 for 10 passages remained stable (Fig S3). These results show that iPSC can be 3D-cultured for extended periods of time in OXS8360 containing medium, reducing aggregation, maintaining pluripotency and facilitating dissociation.

OXS8360 suppresses homophilic interactions between the extracellular domains of E-cadherin in iPSC.

To explore the effect of OXS8360 on iPSC architecture, specifically E-cadherin-associated adherens junctions, OXS8360-treated iPSC were fixed and stained with anti E-cadherin mAb clones 36 and SHE78-7, commercially available antibodies that recognise an intracellular portion and the first extracellular domain (EC1) of E-cadherin respectively^{23, 24}. Fluorescence intensity remained similar between treated and control cells when stained for intracellular E-cadherin (Fig. 6a). In contrast, and consistent with the observed disruption of iPSC

colonies, the fluorescence intensity at cell-cell contacts revealed using the EC1 antibody recognising the extracellular domain was much weaker in OXS8360-treated cells than control cells.

Separation of adjacent epithelial cells has been shown to be induced by disruption of cell-cell E-cadherin interactions. Several examples of mechanisms resulting in loss of this protein's surface expression include internalization of E-cadherin, proteosomal degradation, and proteolytic cleavage²⁵. Cleavage of mature E-cadherin (120 kDa), results in the shedding of a soluble 80 kDa E-cadherin fragment. Therefore, we sought to measure its presence in the supernatant of both treated and untreated iPSC. Cells were plated and grown for 24 hours prior to treatment with 0.1% DMSO (negative control), 50 μ M ethylenediaminetetraacetic acid (EDTA) (used as a positive control shown to enhance E-cadherin cleavage²⁶) or 1 μ M OXS8360 for 24 hours. Soluble E-cadherin released from cultured cells significantly increased in the presence of OXS8360 (Fig. 6b), as measured by ELISA, consistent with the adhesion-inhibitory effects.

PKC modulates iPSC spreading induced by OXS8360.

As OXS8360 has been reported to be a protein kinase C (PKC) activator, binding to the conventional (α , β , γ) and novel (δ , ϵ) PKC isoforms²⁷, we hypothesised that the observed iPSC phenotype may be mediated through this pathway. A comparison with structurally unrelated PKC activators was first carried out. Treatment of iPSC with commercially available phorbol esters (known to be PKC activators²⁸) gave a similar effect on colony disruption to OXS8360 (Fig. S10). We next determined the expression levels of PKC isoforms in iPSC, which have been reported to exhibit tissue-specific levels of expression²⁸. All conventional, novel and atypical PKC isoforms (cPKC, nPKC, aPKC) were expressed in the iPSC line OX1-18, with PKC δ , ι and ζ the most highly expressed. With the exception of PKC δ , no significant differences in the expression of isoforms were observed upon 72h treatment with OXS8360 compared with untreated cells (Fig. 6c).

In addition, using a relative kinase assay, we observed that 1 μ M OXS8360 induced a statistically significant increase in PKC enzymatic activity in iPSC (Fig. 6d).

190 Finally, two pharmacological PKC inhibitors, namely Gö6976 and Gö6983, were tested for their ability to block
 191 OXS8360-induced morphological change in iPSC. These inhibitors have been shown to inhibit PKC isoforms
 192 at nanomolar concentrations^{29, 30}. Gö6976 has been reported to be a specific inhibitor of the conventional
 193 PKC isoforms α and β whereas Gö6983 acts as pan-PKC inhibitor with more affinity for conventional and novel
 194 isoforms than atypical isoforms^{29, 30}. While blocking the PKC pathway with conventional PKC inhibitor Gö6976
 195 had no effect, pan-PKC inhibitor Gö6983 reversed the effect of OXS8360 on colony disruption (Fig. 6e),
 196 suggesting the effects of OXS8360 may be mediated via unconventional PKC isoforms.

197

198 Taken together this data suggests that the effect of OXS8360 may be mediated at least in part through the
 199 activation of novel PKC isoforms.

200

201 **Discussion.**

202 This study has identified a small molecule, OXS8360, which overcomes some of the limitations in iPSC culture
 203 by reversibly disrupting 2D colonies and 3D aggregates, thereby allowing more homogeneous cultures. Our
 204 phenotypic studies were reproducible across four genetically distinct iPS cell lines, overcoming inherent iPSC
 205 line-to-line variability and molecular heterogeneity³¹.

206

207 OXS8360-treated 2D-cultured cells displayed remodelling of the actin cytoskeleton and less tightly-packed
 208 colonies. However, note that we could not confirm total contact-independence. OXS8360-treated 3D-
 209 cultured cells displayed smaller, looser aggregates, resulting in a more homogeneous cell population, with
 210 improved dissociation capacity. This overcomes several limitations of current 3D aggregate systems,
 211 especially transport of nutrients and small molecules that play an important role in pluripotency
 212 maintenance^{6, 32}.

213

214 OXS8360-treated iPSC maintained a highly proliferative self-renewal capacity³³ (assessed by Ki-67 staining
 215 and cumulative cell-count), and a pluripotent signature, shown by expression of widely accepted markers³⁴,
 216 ScoreCard assay, undirected differentiation into all three germ layers, and directed differentiation to

217 mesodermal (macrophages) and neurectodermal (cerebral cortical neurons) lineages. Extended culture for
218 10 passages demonstrated that OXS8360-treated iPSC preserved their key iPSC characteristics, including
219 karyotypic stability. Therefore, OXS8360 is fully compatible with iPSC functionality over extended passaging.

220

221 To elucidate the mechanism of action of OXS8360, and consistent with previous reports²⁷, we showed that
222 OXS8360 increased PKC activity in iPSC. PKC is a pleiotropic enzyme, but also mediates the tumour-promoting
223 activity of phorbol esters and certain teleocidin natural products, including (-)-ILV³⁵. The tumor-promoting
224 potential of the phorbol ester TPA is context dependent³⁵, and structure-activity-relationship analysis of (-)-
225 ILV has demonstrated that tumour-promoting activity is not observed across all related structures and not
226 necessarily dependent on PKC activation³⁶. Furthermore activation of PKC by other chemotypes (e.g.
227 bryostatin) has been demonstrated to lack tumour-promotor activity³⁷. PKC activators have not been
228 reported as tumour *initiators*, and importantly in our study we see no evidence of any effect on genome
229 integrity or proliferation rate following OXS8360-treatment.

230

231 All cPKCs, nPKCs and aPKCs isozyme transcripts were detectable in iPSC. However, it remains unclear whether
232 OXS8360 exerts its effects through specific PKC isozymes. Moreover, specific PKC isoforms³⁸ or exposure to
233 activators³⁵ can have opposing effects in different cell types, depending on the stimulus and PKC intracellular
234 localisation. Therefore we compare our results here with other reports studying PKC isoform effects in
235 epithelial cell types. The effect of OXS8360 on iPSC was not abrogated by Gö6976 (a PKC α and β inhibitor),
236 however, this does not rule out an effect mediated by PKC γ . In rabbit lens epithelial cells, PKC γ has been
237 reported to play a role in the regulation of the gap junction protein, connexin 43³⁹. Of the nPKCs, PKC ϵ has
238 been shown to suppress adherens junctions through adducin⁴⁰, weaken tight junctions through claudin-4⁴¹
239 and promote epithelial-mesenchymal transition (EMT)⁴². PKC δ has been shown to modulate cell scattering
240 in MDCK cells²³ and human keratinocytes⁴³. Both studies suggest that PKC δ might interfere with homophilic
241 interactions between E-cadherin ectodomains, thus suppressing adherens junctions. Meanwhile, Oh *et*
242 *al.*⁴⁴ reported the involvement of PKC δ in the regulation of peripheral actin organization and cell-cell contacts
243 in the epithelium. Interestingly, PKC δ was found to be the most highly expressed isoform in iPSC.

244

245 OXS8360-treated iPSC shed more E-cadherin into the medium, and the E-cadherin ectodomain
246 (immunostaining with antibody SHE78-7) decreased, whereas the cytoplasmic domain of E-cadherin
247 (antibody clone 36) was unchanged, as previously observed²³. It is possible that PKC directly phosphorylates
248 the cytoplasmic domain of E-cadherin causing a conformational change on the ectodomains, disfavoring the
249 homophilic binding of the ectodomains of E-cadherin, identified as cleavage sites for proteases^{45,46}.
250 Alternatively, other proteins involved in the assembly of adherens junctions may be phosphorylated by PKC
251 activation indirectly. PKC-mediated phosphorylation of β -catenin negatively regulates the Wnt/ β -catenin
252 pathway leading to disconnection of its interaction with cytoplasmic E-cadherin⁴⁷. Overall we propose that
253 activation of PKC leads to weakening of cell-cell junctions and shedding of soluble E-cadherin, although
254 further studies will be necessary to clarify which PKC isoform or isoforms are involved and the intermediate
255 mechanistic steps.

256

257 **Conclusion**

258 In summary, we have identified a small molecule additive, OXS8360, which enables more uniform 2D and 3D
259 culture of iPSC without compromising potency or genetic integrity. In 3D culture systems, our approach
260 reduces the number of culture components needed, as no hydrogel or microcarrier-based culture is required
261 to control aggregate size. The looser and smaller aggregates facilitate maintenance and expansion of iPSC
262 while also overcoming issues of diffusion and homogeneity. This approach will improve the efficiency and
263 reproducibility of hPSC culture at scale.

264

265 **Statistical analysis**

266 GraphPad Prism was used for statistical analysis. One-way ANOVA with Sidak's or Dunnett's multiple
267 comparisons or paired two-tailed t test were used as indicated. Values are indicated in figures as *p < 0.05,
268 **p < 0.01, ***p < 0.001, ****p < 0.0001, and n.s. (not significant).

269

270

271 **Methods**

272 ***Cell lines and culture***

273 This study was carried out using four reprogrammed iPSC lines (Table S1), with human dermal fibroblasts
274 (HDF) as a control where necessary. The iPSC and HDF were all derived in Oxford from healthy control donors
275 recruited through the Oxford Parkinson's Disease Centre - participants were recruited having given signed
276 informed consent, which included derivation of hiPSC lines from skin biopsies (Ethics Committee, National
277 Health Service Health Research Authority, NRES Committee South Central, Berkshire, UK, REC 10/H0505/71).
278 All experiments were performed in accordance with UK guidelines and regulations and as set out in the REC
279 and the iPSC lines used have all been published previously (Table S1).

280 iPSCs were maintained in 2D feeder-free conditions on hESC-qualified Matrigel (Corning), or Geltrex (Life
281 Technologies) in complete mTeSR™1 (Stem Cell Technologies) supplemented with 100 units/mL of penicillin-
282 streptomycin (Gibco™) at 37°C in a humidified atmosphere with 5% CO₂. At approximately 80% confluence,
283 cells were dissociated for 5 min at 37°C in prewarmed TrypLE Express (Gibco™). TrypLE Express was then
284 diluted 1:10 in prewarmed 1x Dulbecco's phosphate-buffered saline (DPBS), and cells centrifuged for 5 min
285 at 400 rcf. Supernatant was removed and cell pellets were gently resuspended to give a single cell suspension
286 in medium supplemented with 10 µM ROCK inhibitor Y-27632 (Sigma-Aldrich). Daily medium change was
287 performed by replacing the medium with fresh mTeSR™ without ROCK inhibitor Y-27632.

288 For static suspension cultureⁱ, 6-well plates with repellant surfaces were used (Greiner Bio-One™). 3 mL of a
289 cell suspension at a density of 0.33x10⁶ cells/mL were supplemented with 100 units/mL penicillin-
290 streptomycin and 10 µM ROCK inhibitor Y-27632. Aggregates were allowed to form at 37°C in a humidified
291 atmosphere with 5% CO₂ over 4 days with no medium change. On day 4 of suspension culture, aggregates
292 were transferred to 15-mL tubes. Supernatant was removed after centrifugation at 400 rcf for 5 min. This
293 was followed by incubation in 1 mL of TrypLE for 5 min in a water bath set at 37°C. Cells were centrifuged at
294 300 rcf for 4 min to remove the supernatant and resuspended in 1 mL of mTeSR™ prior to filtration through
295 a 30 µm sieve. The membrane was washed with 1 mL mTeSR™ and cells were resuspended in the appropriate

296 volume of ROCK inhibitor Y-27632 supplemented mTeSR1™. A dedicated incubator was used to prevent
297 inadvertent agitation of the cultures through door opening/closing.

298 When treated with compounds for experiments, cells were cultured in the presence of 0.1% DMSO, 1 μM (-
299)-ILV, or 1 μM OXS8360 unless stated otherwise. Cell phenotype was monitored by using phase contrast
300 microscopy with an EVOS XL cell imaging system.

301 HDFs were cultured in T-25 flasks (Corning) at 37°C and 5% CO₂ with 6 mL HDF medium consisting of 1x
302 Advanced DMEM (Gibco™), 1x Glutamax™ (Gibco™), 100 μM β-mercaptoethanol (Gibco™), 0.1x fetal
303 bovine serum (Sigma). Medium was changed every 4 days and cell passaging was as described for iPSCs.

304

305 ***Caspase activity assay***

306 Measurements of caspase activities in cells were performed using the commercially available Caspase-Glo
307 3/7 Assay (Promega, Madison, WI) according to the manufacturer's instructions. A previous experiment for
308 the determination of the cell density revealed an optimal linear range of the assay at 10.000 cells/well in a
309 96 well format.

310

311 ***Annexin V assay***

312 iPSCs were seeded at a density of 1x10⁵ cells/well onto a 24-well plate, and treated for 24h, 48h and 72h
313 with 1 μM of (-)-ILV or 0.1% DMSO and apoptotic cells were analyzed by using Annexin V FITC apoptosis
314 detection kit (Abcam). Following treatment, cells were washed with 500 μL Hank's Balanced Salt Solution
315 (HBSS, Gibco™) and dissociated as described above. Centrifugation was 400 rcf for 5 min and pellets
316 resuspended in a 100 μL 1x binding buffer. Further incubation was performed with 5 μL of FITC-conjugated
317 Annexin V and 5 μL of propidium iodide for 15 min in the dark. Prior to analysis, 200 μL of binding buffer was
318 added to each sample. Quantification was realized by flow cytometry and data analyzed using FlowJo
319 software.

320

321 ***Flow cytometry***

322 For assessing cell surface antigens, 30 min staining on ice was carried out on fresh cells in cold FACS buffer
 323 consisting of PBS, 10 µg/mL human IgG (Sigma), 1% FBS (Hyclone) and 0.01% sodium azide prior to fixation.
 324 For intracellular antigens, staining was carried out on cells fixed with 4% paraformaldehyde (PFA) in PBS for
 325 10 min and stored in methanol at -20°C for up to 4 weeks. Cells were stained at a density of 1x10⁶ cells/mL
 326 in a total of 100 µL FACS buffer with the appropriate antibody or isotype-matched control in a V-bottom 96-
 327 well plate. For two-colour staining, two antibodies or two isotype controls (attached to different
 328 fluorophores) were added together. Following an incubation of 90 min at room temperature, cells were
 329 washed three times with FACS buffer. When using unconjugated antibodies, a further incubation of 40 min,
 330 at room temperature, was performed with a secondary antibody. Samples were washed another 3 times and
 331 analysed using FACS Calibur flow cytometer (Becton Dickinson). Data were analysed using FlowJo software
 332 and antibodies used are described in the table below.

333

Product	Host	Isotype, conjugate fluorophore	Supplier	[c]	Catalogue number
Anti-CD44	Mouse	IgG ₁ , FITC	Life Technologies	1:40	11044182
Anti-SSEA3	Rat	IgGM, Alexa Fluor 488	Biolegend	1:80	330306
Anti-SSEA4	Mouse	IgG ₃ , APC	R&D	1:20	FAB1435A
Anti-Tra1-60	Mouse	IgM, PE	Biolegend	1:10	330609
Anti-Tra1-60	Mouse	IgM, Alexa Fluor 488	Biolegend	1:10	330613
Anti-Nanog	Rabbit	IgG, Alexa Fluor 647	Cell Signaling	1:10	5448S
Anti-KI-67	Mouse	IgG ₁	Merck	1:400	MAB4190
Anti-CD11b	Mouse	IgG ₁ , APC	Biolegend	1:25	301309
Anti-CD14	Mouse	IgG ₁ , PE	ImmunoTools	1:25	21620144
Anti-CD45	Mouse	IgG ₁ , APC	ImmunoTools	1:25	21270456

Isotype control	Mouse	IgG ₁ , FITC	Biolegend	1:50	400107
Isotype control	Rat	IgM, Alexa Fluor 488	Biolegend	1:100	400811
Isotype control	Mouse	IgG ₃ , APC	R&D	1:20	IC007A
Isotype control	Mouse	IgM, Alexa Fluor 488	Biolegend	1:10	401617
Isotype control	Rabbit	IgG, Alexa Fluor 647	Cell Signaling	1:10	2985S
Secondary antibody	Donkey	IgG, anti-mouse Alexa Fluor 647	Invitrogen	1:1000	A-31571
Secondary antibody	Goat	IgM, anti-mouse, Alexa Fluor 488	Invitrogen	1:1000	A-21042
Secondary antibody	Goat	IgG _{2a} , anti-mouse, Alexa Fluor 647	Invitrogen	1:1000	A-21241
Secondary antibody	Goat	IgG, anti-rabbit, Alexa Fluor 647	Invitrogen	1:1000	A-21244

334

335 ***Undirected differentiation***

336 iPSC were washed with PBS and harvested by incubating the cells for 5 min at 37°C with 1 mL warm TrypLE
337 Express (Gibco™). The cells and TrypLE were well mixed into a single cell suspension by pipetting up and
338 down and collected in a 15 mL centrifuge tube and diluted 1:10 with PBS. Cells were counted and spun down.
339 After centrifugation PBS was aspirated and the cell pellet was tapped loose and resuspended in mTeSR™-1
340 spin-EB medium consisting of mTeSR™-1 (Stem Cell Technologies), supplemented with 1 mM Rock-inhibitor
341 (Y27632, Calbiochem). For AggreWells™800 (Stemcell Technologies, 300 micro-wells), plates were first
342 prepared After preparing the plate, 1 mL of 4×10⁶ PSC were added per well. The plate containing PSC and 2
343 mL of spin-EB medium per well was centrifuged at 800 rpm for 3 minutes. The plate was examined under the
344 microscope to verify cells were evenly distributed among the micro-wells. Very gently the plate was put into
345 the incubator and left for four days. The EBs were fed daily with spin-EB medium (first brought to RT), by

346 gently aspirating 1 mL medium using a p1000 Gilson and very gently adding 1 mL fresh spin-EB medium in a
347 drop-wise manner down the side of the well so the EBs were not washed out of the microwells. This wash
348 was repeated to achieve a 75% medium change overall. To harvest EBs at day 4, the contents of the wells
349 were pipetted up and down several times using a 5 mL serological pipette to dislodge the EBs from the micro-
350 wells. The contents were taken up and transferred onto a 40 µM cell strainer inverted over a 50 mL centrifuge
351 tube. The inverted strainer, with the EBs balanced on top, was carefully inverted over onto a new 50 mL
352 centrifuge tube so that the EBs were now at the bottom of the strainer and could be collected into the new
353 50 mL tube, by passing through 4 mL of relevant differentiation medium. The strainer was held at an angle
354 to facilitate the collection of EBs. The EBs for each condition were then plated split into half and plated onto
355 a Geltrex pre-coated 60mm petri dish (Corning) for the TaqMan hPSC Scorecard™ Panel assay.

356

357 ***TaqMan hPSC Scorecard™ Panel assay***

358 To form EBs, the manufacturer's protocol described in the user guide for the TaqMan hPSC Scorecard™ Panel
359 (Applied Biosystems™) was adapted. EBs were generated according to the EB-spin formation protocol and
360 harvested on day 4 as outlined above. Between day 4 and 14, a 75% medium change was performed only
361 every other day. On day 14, each cell culture dish was harvested. The culture medium was removed and cells
362 were gently washed in 5mL PBS for 2 minutes. 700 µl RLT buffer (Qiagen) was pipetted onto each plate
363 supplemented with 1% of β-mercaptoethanol (Sigma) to reduce RNase activity. Upon cell lysis, a cell scraper
364 (Sarstedt) was used to collect the remaining cell content. After careful homogenisation by using a Gilson
365 p1000, the total of 700µl slurry was transferred in aliquots of 350 µl onto two QIAGEN shredder membranes
366 (Qiagen), and stored at -80°C.

367

368 ***Directed differentiation to macrophages***

369 iPSCs were differentiated to macrophages as previously described by van Wilgenburg *et al.*ⁱⁱ. Briefly, 3×10^6
370 iPSCs were seeded into an Aggrewell 800 well (STEMCELL Technologies) to form EBs, in mTeSR1 and fed daily
371 with medium plus 50 ng/mL BMP4 (Peprotech), 50 ng/mL VEGF (Peprotech), and 20 ng/mL SCF (Miltenyi
372 Biotec). Four-day EBs were then differentiated in T175 flasks (150 EBs) in X-VIVO15 (Lonza), supplemented

with 100 ng/mL M-CSF (Invitrogen), 25 ng/mL IL-3 (R&D), 2 mM Glutamax (Invitrogen), 100 U/mL penicillin and 100 µg/mL streptomycin (Invitrogen), and 0.055 mM β-mercaptoethanol (Invitrogen), with fresh medium added weekly. Macrophage precursors (pMacpre) emerging into the supernatant after approximately 1 month were collected weekly and differentiation cultures replenished with fresh medium. Harvested cells were strained (40 µm, Corning) and plated onto tissue-culture treated plastic at 100,000 per cm² and differentiated for 8 days to adherent macrophages (pMac) in X-VIVO15 with 100 ng/mL M-CSF, 2 mM Glutamax, 100 units/mL penicillin-streptomycin.

380

381 ***Directed differentiation to cortical neuron progenitors***

iPSCs were differentiated to cortical neuron progenitors (NPCs)ⁱⁱⁱ with the following modifications: feeder-free iPSCs were plated onto Matrigel-coated 6-well plates, with neural induction for 12 days using dual SMAD inhibition; after replating the neuroepithelial sheet on precoated wells with 20 µg/mL of laminin at day 12 using dispase II, 20 ng/mL fibroblast growth factor 2 (FGF2, R&D) was added to neural maintenance medium (NMM) from days 12 to 15. Thereafter, a full medium change was performed every other day. On day 18, newly formed rosettes were passaged either with dispase II or manually. For the latter, rectangles containing rosettes were cut with a needle, and in case of large size, scored into multiple rectangles. The cell sheets were then lifted manually, collected with a Gilson p200 and transferred in 2mL of NMM onto a new well precoated with 20µg/mL laminin. Between day 18 and 25, a full medium change was performed every other day, and cells were stained on day 25 for confocal imaging.

392

393 ***Immunocytochemistry***

Undifferentiated iPSCs on Geltrex coated µ-slides were prepared for immunofluorescence microscopy as followed. E-cadherin expression was monitored for cells seeded overnight prior to 24h treatment with 0.1% DMSO, 1 µM ILV or 1 µM OXS8360. When looking at the expression of KI-67, Tra 1-60 or Nanog cells were treated for 3 passages. Treated iPSCs were fixed with 4% PFA for 10 minutes at room temperature, permeabilised and blocked with 10% goat serum and 0.3% Triton X-100 in PBS overnight at 4°C prior to washing 3 times with PBS and 0.3% Triton X-100. Anti-E-cadherin (2.5 µg/mL, clone 36, BD Transduction

400 Laboratories or SHE78-7, Invitrogen), anti-KI-67 (1:400, Merck), anti-Tra-1-60 PE (conjugated, 1:10,
401 Biolegend), anti-Nanog Alexa Fluor 647 (conjugated, 1:10, Biolegend) antibodies were diluted in antibody
402 solution (PBS, 1% bovine serum albumin (BSA), 0.1% Triton X-100) and incubated overnight at 4°C. When
403 using unconjugated antibodies, wells were washed prior to applying Alexa Fluor 647 (goat-anti-rabbit, IgG,
404 1:1000) diluted in antibody solution (PBS, 1% BSA, 0.3% Triton-X) for 2 hours at room temperature.

405 For cortical neuronal progenitors, pretreated cells with 0.1% DMSO or 1 µM OXS8360 were passaged on day
406 18 onto precoated µ-slides and grown until day 25. Cells were fixed with 4% PFA for 10 minutes at room
407 temperature, permeabilised and blocked with PBS, 1% donkey serum/1% goat serum, 0.3% Triton-X
408 overnight at 4°C. Anti-PAX-6 (1:300, Covance) and anti-TUJ-1 (1:200, Covance) were used as primary
409 antibodies, and Alexa 488 (goat-anti-mouse, IgM, 1:1000) or Alexa Fluor 647 (goat-anti-rabbit, IgG, 1:1000)
410 were stained for visualization.

411 After washes, nuclei were counterstained with Hoechst 33342 or DAPI for 30 minutes at room temperature.
412 Fluorescent images were acquired using the FV1200 (Olympus) confocal microscope. All antibodies used are
413 described in the table below.

414

Product	Host	Isotype, conjugate fluorophore	Supplier	[c]	Catalogue number
Anti-E-cadherin, clone 36	Mouse		BD Transduction Laboratories	2.5 µg/mL	610182
Anti-E-cadherin, clone SHE78-7	Mouse		Invitrogen	2.5 µg/mL	13-5700
Anti-Tra1-60	Mouse	IgM, PE	Biolegend	1:10	330609
Anti-Nanog	Rabbit	IgG, Alexa Fluor 647	Cell Signalling	1:10	5448S
Anti-KI-67	Mouse	IgG ₁	Merck	1:400	MAB4190
Anti-PAX-6	Rabbit	IgG (polyclonal)	Covance	1:300	PRB-278P

Anti-TUJ1	Mouse	IgG _{2a}	Covance	1:200	MMS-435P
Secondary antibody	Donkey	IgG, anti-mouse Alexa Fluor 647	Invitrogen	1:1000	A-31571
Secondary antibody	Goat	IgM, anti-mouse, Alexa Fluor 488	Invitrogen	1:1000	A-21042
Secondary antibody	Goat	IgG, anti-rabbit, Alexa Fluor 647	Invitrogen	1:1000	A-21244

Enzyme-linked Immunosorbent Assay for soluble E-Cadherin

Cells were seeded in a 6-well plate at a density of 1×10^6 cells per well for 24 h prior to starting any treatment. Medium was removed and a further incubation was realized in presence of 0.1% DMSO, 1 μ M OXS8360 or 50 μ M EDTA in fresh mTeSRTM. Medium from each condition was removed and E-cadherin concentrations were quantified by using Human E-Cadherin Quantikine ELISA kit (Invitrogen). The Human E-Cadherin EIA kit protocol was followed as described. Briefly, 100 μ L of all sample or standard were added to appropriate wells prior to incubating the microtiter plate for 2 h at 37°C. The sample solutions were removed and each well was washed with 3 x 350 μ L 1x Wash Buffer. Between each wash, the plate was emptied out and tapped vigorously onto paper towel, especially after the last washing. 100 μ L of Antibody-HRP Conjugate Solution was added into each well followed by a 1 h incubation at 37°C. Sample solutions were removed and wells were washed 4 times as described above. 100 μ L of Substrate Solution were added into each wells followed by a further incubation at 30°C for 30 min. 100 μ L of Stop Solution was then added to each well before recording the absorbance at OD = 450 nm.

Quantitative real-time PCR (qRT-PCR)

RNA extraction

RNA was either extracted from cell pellets that had previously been stored at -80°C, or from cell slurry. For lysis, 350 μ L RLT buffer supplemented with 1% pure β -mercaptoethanol were added and the cell slurry was

transferred onto a QIAshredder spin column (Qiagen). Subsequently, cell lysates were spun on the QIAshredder column and RNA extracted using the RNeasy kit (Qiagen) according to the manufacturer's protocol. An optional on-column DNase treatment for 15 minutes was performed. RNA yields were measured by loading 1.5 µL of extracted RNA onto the NanoDrop™ 2000c spectrophotometer. The optical density of each sample was subsequently verified for its purity (A 260/280 ratio = 2).

cDNA production by reverse transcription (RT)

cDNA was produced by using either the Ambion RETROScript™ Kit (Invitrogen) or the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), and in both cases a total of 1 µg RNA/sample was loaded for the cDNA reaction. For the TaqMan hPSC Scorecard™ Panel, cDNA was produced using the High Capacity cDNA Reverse Transcription Kit according to the manufacturer's protocol.

Quantitative real-time PCR (qRT-PCR)

qRT-PCR was either performed using a SYBR Green- (Applied Biosystems) or a TaqMan-based approach. To this end, the previously generated cDNA was diluted and prepared according to tables below. The primers for PKC isoforms and E-cadherin were adopted from Awadelkarim *et al.*^{iv} and Labernadie *et al.*^v and ordered from Sigma. Prior to all experiments, the efficiencies of the endogenous control (TBP) and the primer pairs were tested (Fig. S11).

Table 1: SYBR Green sample preparation

	Primer mix (5 µL each)	2 x SYBR Select MM	Nuclease-free H ₂ O	Total volume
SYBR Green reaction				
Volume/sample +	0.5 µL	12.5 µL	10 µL	23 µL
1.8 µL template cDNA (20 µL cDNA reaction diluted 1:10 in H ₂ O)				25 µL

Table 2: TaqMan sample preparation

	TaqMan primer	TaqMan Gene Expression MM	Nuclease-free H ₂ O	Total volume
--	------------------	------------------------------	-----------------------------------	--------------

TaqMan reaction

Volume/sample	1 µL	10 µL	7.2 µL	18.2 µL
+				
1.8 µL template cDNA (20 uL cDNA reaction diluted 1:10 in H ₂ O)				25 µL

The total volume of master mix and cDNA was loaded onto a MicroAmp™ Optical 96-Well Reaction Plate (Applied Biosystems), and the qRT-PCR reaction run on the StepOnePlus™ Real-Time PCR System (Applied Biosystems). Analysis of relative gene expression levels was performed according to the $\Delta\Delta CT$ approach^{vi}.

Enzyme-linked Immunosorbent Assay for PKC activity

PKC activity was tested using PKC kinase activity assay (Abcam) according to the manufacturer's protocol. Briefly, cells treated for 1 passage (5 days) with 0.1% of DMSO or 1 µM of OXS8360 were incubated with lysis buffer (20 mM MOPS, 50 mMβ-glycerolphosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 5 mM EGTA, 2 mM EDTA, 1% NP40, 1 mM DTT, 1 mM benzamidine, 1 mM PMSF, 10µg/ml leupeptin and aprotinin) for 10 min on ice and then centrifuged at 13000 rpm for 15 min. 0.3 µg of protein from cell lysates diluted in 30µl of Kinase Assay Dilution Buffer were added to the pre-soaked wells of the PKC substrate microtiter plate. Standard diluted in 30µl of Kinase Assay Dilution Buffer and 30 µl of Kinase Assay Dilution Buffer (blank) were also added in appropriate wells. The kinase reaction was initiated by adding 10 µl of ATP to each well and the samples were incubated for 90 min at 30°C with gentle shaking after 20 min. The reaction was stopped by removing the contents of each well. Samples, excluding blank ones, were incubated with 40 µl of Phosphospecific substrate antibody for 1 h at room temperature with gentle shaking every 20 min. Wells were washed four times with Wash Buffer and then incubated with 40 µL of diluted anti-rabbit IgG-HRP antibody for 30 min at room temperature, with gentle shaking every 10 min. Subsequently, all wells were washed four times with Wash Buffer. In order to detect PKC activity, 60 µL of TMB substrate was added to each well and the plate was incubated at room temperature for 60 min and then stopped by addition of 20 µL of Stop Solution. The PKC activity was analyzed by measuring the absorbance at OD = 450 nm.

Methods references

- ⁱ Zweigerdt, R., Olmer, R., Singh, H., Haverich, A. & Martin, U. Scalable expansion of human pluripotent stem cells in suspension culture. *Nat Protoc* **6**, 689-700 (2011)
- ⁱⁱ van Wilgenburg, B., Browne, C., Vowles, J. & Cowley, S.A. Efficient, long term production of monocyte derived macrophages from human pluripotent stem cells under partly-defined and fully-defined conditions. *PLoS One* **8**, e71098 (2013).
- ⁱⁱⁱ Shi, Y., Kirwan, P. & Livesey, F.J. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. *Nat Protoc* **7**, 1836-1846 (2012).
- ^{iv} Awadelkarim, K.D. et al. Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: evidence that PKC λ overexpression is an independent prognostic factor. *Int J Cancer* **131**, 2852-2862 (2012).
- ^v Labernadie, A. et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables fibroblasts to drive cancer cell invasion. *Nat Cell Biol* **19**, 224-237 (2017).
- ^{vi} Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2^{-Delta Delta C(T)} Method. *Methods* **25**, 402-408 (2001).

Acknowledgments

Financial support: The Wellcome Trust WT155121302 and the Oxford Martin School LC0910-004 (James Martin Stem Cell Facility, Oxford, S.A.C.). The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115439, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007–2013) and EFPIA companies' in kind contribution. This publication reflects only the author's views and neither the IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. This work was also supported by funding from Oxstem Limited. We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics, Oxford (Funded by Wellcome Trust grant reference 090532/Z/09/Z and MRC Hub grant G0900747 91070) for the generation of Illumina SNP data.

Author contributions

Conceptualization, S.A.C., A.J.R., W.S.J., L.S., G.L. and S.G.D.; Formal analysis, L.S., M.Sc, G.L., M.O., L.G.-P., E.C., C.J.R.B. and M.St.; Funding acquisition, S.A.C., A.J.R., W.S.J. and S.G.D.; Investigation, L.S., M.Sc., G.L., M.O., E.C., C.J.R.B. and M.St.; Methodology, L.S., M.Sc., G.L., M.O., L.G.-P., E.C., C.J.R.B. and M.St.; Resources, S.A.C., A.J.R., W.S.J. and L.W.S.; Supervision, S.A.C., W.S.J. and A.J.R.; Writing – original draft, L.S.; Writing – review and editing, S.A.C. and A.J.R.

510

511 Competing interests statement

512 The authors declare that they have no competing interests.

513 S.G.D. and A.J.R. are co-founders and minor equity holders in Oxstem Ltd.

514

515 References

- 516 1. Kimbrel, E.A. & Lanza, R. Current status of pluripotent stem cells: moving the first therapies to the
517 clinic. *Nat Rev Drug Discov* **14**, 681-692 (2015).
- 518 2. Chen, K.G., Mallon, B.S., McKay, R.D. & Robey, P.G. Human pluripotent stem cell culture:
519 considerations for maintenance, expansion, and therapeutics. *Cell Stem Cell* **14**, 13-26 (2014).
- 520 3. Ludwig, T.E. et al. Feeder-independent culture of human embryonic stem cells. *Nat Methods* **3**, 637-
521 646 (2006).
- 522 4. Chen, G. et al. Chemically defined conditions for human iPSC derivation and culture. *Nat Methods*
523 **8**, 424-429 (2011).
- 524 5. Zweigerdt, R., Olmer, R., Singh, H., Haverich, A. & Martin, U. Scalable expansion of human
525 pluripotent stem cells in suspension culture. *Nat Protoc* **6**, 689-700 (2011).
- 526 6. Edmondson, R., Broglie, J.J., Adcock, A.F. & Yang, L. Three-dimensional cell culture systems and
527 their applications in drug discovery and cell-based biosensors. *Assay Drug Dev Technol* **12**, 207-218
528 (2014).
- 529 7. Ekerdt, B.L. et al. Thermoreversible Hyaluronic Acid-PNIPAAm Hydrogel Systems for 3D Stem Cell
530 Culture. *Adv Healthc Mater* **7**, e1800225 (2018).
- 531 8. Kempf, H., Andree, B. & Zweigerdt, R. Large-scale production of human pluripotent stem cell
532 derived cardiomyocytes. *Adv Drug Deliv Rev* **96**, 18-30 (2016).
- 533 9. Soncin, F. et al. Abrogation of E-cadherin-mediated cell-cell contact in mouse embryonic stem cells
534 results in reversible LIF-independent self-renewal. *Stem Cells* **27**, 2069-2080 (2009).
- 535 10. Segal, J.M. & Ward, C.M. Novel peptides for deciphering structural and signalling functions of E-
536 cadherin in mouse embryonic stem cells. *Sci Rep* **7**, 41827 (2017).
- 537 11. van Wilgenburg, B., Browne, C., Vowles, J. & Cowley, S.A. Efficient, long term production of
538 monocyte-derived macrophages from human pluripotent stem cells under partly-defined and fully-
539 defined conditions. *PLoS One* **8**, e71098 (2013).
- 540 12. Haenseler, W. et al. Excess α -synuclein compromises phagocytosis in iPSC-derived macrophages.
541 *Scientific reports* **7** (2017).
- 542 13. Davidson, A.J. & Wood, W. Unravelling the Actin Cytoskeleton: A New Competitive Edge? *Trends*
543 *Cell Biol* **26**, 569-576 (2016).
- 544 14. Närvä, E. et al. A Strong Contractile Actin Fence and Large Adhesions Direct Human Pluripotent
545 Colony Morphology and Adhesion. *Stem Cell Reports* **9**, 67-76 (2017).
- 546 15. Scholzen, T. & Gerdes, J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* **182**,
547 311-322 (2000).
- 548 16. Quintanilla, R.H., Asprer, J.S., Vaz, C., Tanavde, V. & Lakshmipathy, U. CD44 is a negative cell surface
549 marker for pluripotent stem cell identification during human fibroblast reprogramming. *PLoS One* **9**,
550 e85419 (2014).
- 551 17. Bock, C. et al. Reference Maps of human ES and iPSC cell variation enable high-throughput
552 characterization of pluripotent cell lines. *Cell* **144**, 439-452 (2011).
- 553 18. Tsankov, A.M. et al. A qPCR ScoreCard quantifies the differentiation potential of human pluripotent
554 stem cells. *Nat Biotechnol* **33**, 1182-1192 (2015).

- 555 19. Doetschman, T.C., Eistetter, H., Katz, M., Schmidt, W. & Kemler, R. The in vitro development of
556 blastocyst-derived embryonic stem cell lines: formation of visceral yolk sac, blood islands and
557 myocardium. *J Embryol Exp Morphol* **87**, 27-45 (1985).
- 558 20. Pettinato, G., Wen, X. & Zhang, N. Formation of well-defined embryoid bodies from dissociated
559 human induced pluripotent stem cells using microfabricated cell-repellent microwell arrays. *Sci Rep*
560 **4**, 7402 (2014).
- 561 21. Buchrieser, J., James, W. & Moore, M.D. Human Induced Pluripotent Stem Cell-Derived
562 Macrophages Share Ontogeny with MYB-Independent Tissue-Resident Macrophages. *Stem Cell*
563 *Reports* **8**, 334-345 (2017).
- 564 22. Shi, Y., Kirwan, P. & Livesey, F.J. Directed differentiation of human pluripotent stem cells to cerebral
565 cortex neurons and neural networks. *Nat Protoc* **7**, 1836-1846 (2012).
- 566 23. Chen, C.L. & Chen, H.C. Functional suppression of E-cadherin by protein kinase Cdelta. *J Cell Sci* **122**,
567 513-523 (2009).
- 568 24. Brouxhon, S.M. et al. Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1)
569 suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways. *Clin*
570 *Cancer Res* **19**, 3234-3246 (2013).
- 571 25. Noë, V. et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1.
572 *J Cell Sci* **114**, 111-118 (2001).
- 573 26. Katayama, M. et al. Soluble E-cadherin fragments increased in circulation of cancer patients. *Br J*
574 *Cancer* **69**, 580-585 (1994).
- 575 27. Kozikowski, A.P., Ma, D., Du, L., Lewin, N.E. & Bumberg, P.M. Effect of alteration of the heterocyclic
576 nucleus of ILV on its isoform selectivity for PKC. Palladium catalyzed route to benzofuran analogues
577 of ILV. *Farmaco* **50**, 425-430 (1995).
- 578 28. Steinberg, S.F. Structural basis of protein kinase C isoform function. *Physiol Rev* **88**, 1341-1378
579 (2008).
- 580 29. Wu-Zhang, A.X. & Newton, A.C. Protein kinase C pharmacology: refining the toolbox. *Biochem J*
581 **452**, 195-209 (2013).
- 582 30. Martiny-Baron, G. et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö
583 6976. *J Biol Chem* **268**, 9194-9197 (1993).
- 584 31. Kilpinen, H. et al. Common genetic variation drives molecular heterogeneity in human iPSCs. *Nature*
585 **546**, 370-375 (2017).
- 586 32. Yamada, K.M. & Cukierman, E. Modeling tissue morphogenesis and cancer in 3D. *Cell* **130**, 601-610
587 (2007).
- 588 33. Ghule, P.N. et al. Reprogramming the pluripotent cell cycle: restoration of an abbreviated G1 phase
589 in human induced pluripotent stem (iPS) cells. *J Cell Physiol* **226**, 1149-1156 (2011).
- 590 34. Abujarour, R. et al. Optimized surface markers for the prospective isolation of high-quality hiPSCs
591 using flow cytometry selection. *Sci Rep* **3**, 1179 (2013).
- 592 35. Zhu, G. et al. 12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells
593 via inhibiting YAP through AMOT. *Sci Rep* **7**, 44940 (2017).
- 594 36. Irie, K. et al. Biological activities and cellular uptake studies of fluorescent derivatives of indole
595 alkaloid tumor promoter teleocidin. *Int J Cancer* **43**, 513-519 (1989).
- 596 37. Irie, K., Nakagawa, Y. & Ohigashi, H. Toward the development of new medicinal leads with
597 selectivity for protein kinase C isozymes. *Chem Rec* **5**, 185-195 (2005).
- 598 38. Freeley, M., Kelleher, D. & Long, A. Regulation of Protein Kinase C function by phosphorylation on
599 conserved and non-conserved sites. *Cell Signal* **23**, 753-762 (2011).
- 600 39. Akoyev, V. & Takemoto, D.J. ZO-1 is required for protein kinase C gamma-driven disassembly of
601 connexin 43. *Cell Signal* **19**, 958-967 (2007).
- 602 40. Imamdi, R., de Graauw, M. & van de Water, B. Protein kinase C mediates cisplatin-induced loss of
603 adherens junctions followed by apoptosis of renal proximal tubular epithelial cells. *J Pharmacol Exp*
604 *Ther* **311**, 892-903 (2004).
- 605 41. D'Souza, T., Indig, F.E. & Morin, P.J. Phosphorylation of claudin-4 by PKCepsilon regulates tight
606 junction barrier function in ovarian cancer cells. *Exp Cell Res* **313**, 3364-3375 (2007).

- 607 42. Jain, K. & Basu, A. The Multifunctional Protein Kinase C- ϵ in Cancer Development and Progression.
608 *Cancers (Basel)* **6**, 860-878 (2014).
- 609 43. Singh, R., Lei, P. & Andreadis, S.T. PKC-delta binds to E-cadherin and mediates EGF-induced cell
610 scattering. *Exp Cell Res* **315**, 2899-2913 (2009).
- 611 44. Oh, M.A. et al. PKCdelta and cofilin activation affects peripheral actin reorganization and cell-cell
612 contact in cells expressing integrin alpha5 but not its tailless mutant. *J Cell Sci* **120**, 2717-2730
613 (2007).
- 614 45. Provost, E. & Rimm, D.L. Controversies at the cytoplasmic face of the cadherin-based adhesion
615 complex. *Curr Opin Cell Biol* **11**, 567-572 (1999).
- 616 46. van Roy, F. & Berx, G. The cell-cell adhesion molecule E-cadherin. *Cell Mol Life Sci* **65**, 3756-3788
617 (2008).
- 618 47. Gwak, J. et al. Protein-kinase-C-mediated beta-catenin phosphorylation negatively regulates the
619 Wnt/beta-catenin pathway. *J Cell Sci* **119**, 4702-4709 (2006).
- 620 48. Awadelkarim, K.D. et al. Quantification of PKC family genes in sporadic breast cancer by qRT-PCR:
621 evidence that PKC λ overexpression is an independent prognostic factor. *Int J Cancer* **131**, 2852-
622 2862 (2012).
- 623 49. Labernadie, A. et al. A mechanically active heterotypic E-cadherin/N-cadherin adhesion enables
624 fibroblasts to drive cancer cell invasion. *Nat Cell Biol* **19**, 224-237 (2017).
- 625 50. Livak, K.J. & Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative
626 PCR and the 2^{(-Delta Delta C(T))} Method. *Methods* **25**, 402-408 (2001).

627

628 **Figures legends**

629 **Figure 1. Phenotypic changes in iPSC induced by (-)-ILV and OXS8360 at 1 μ M.**

630 (a) Chemical structure of (-)-ILV and OXS8360. (b) Phase contrast images of (-)-ILV or OXS8360-treated iPSC
631 at 3h, 12h and 24h. Colony disruption is observed 3h post treatment onwards. (c) Reversibility of the
632 phenotypic effect induced by (-)-ILV and OXS8360. iPSC were plated with 10 μ M Rho-kinase inhibitor Y-27623
633 (upper panel) then treated for a subsequent 24h with (-)-ILV (left, middle panel) and OXS8360 (right, middle
634 panel), then compounds were washed off (lower panel). (d) Effects of (-)-ILV and OXS8360 on cell density,
635 nuclei area, perimeter, height, geometric mean forward scatter and actin cytoskeleton signal intensity. To
636 determine nuclei area and perimeter, cells were fixed then stained with Hoechst for confocal microscopy
637 analysis. To determine the nuclei height, z-stacks were imaged. Three images of different locations per
638 condition were analysed with CellProfiler software. Statistical analysis was done using a One-way Anova with
639 Dunett's multiple comparison test. Error bars represent SEM. *P<0.05, **P<0.01, ****P<0.0001. (d)
640 Immunofluorescence staining for actin filaments (green) and nuclei (Hoechst, red), showing cytoskeleton
641 remodelling upon treatment with (-)-ILV or OXS8360. Scale bars, 100 μ m.

642

643 **Figure 2. Assessing the proliferation capacity of OXS8360-treated iPSC through the expression of KI-67.**

644 (a) Immunofluorescence staining for KI-67 (red) shows a similar fraction of actively cycling cells in untreated
645 versus iPSC treated with OXS8360 for three passages. Human dermal fibroblasts (HDF) serve as a slowly-
646 proliferating comparison, with low KI-67 staining. Right hand panel, secondary antibody-only staining control.
647 Scale bars, 50 μ m. (b) Representative flow cytometry plots of KI-67⁺ cells. Black line and grey filled plots
648 represent KI-67 stained population and negative control respectively. Debris and dead cells are gated out.
649 Positive gate is set where negative control $\leq 1\%$. (c) Histograms for KI-67 positive populations in OXS8360-
650 treated iPSC (mean $\pm$ SEM: 99.4 $\pm$ 0.05; n=3), DMSO-treated iPSC (mean $\pm$ SEM: 99.0 $\pm$ 0.12; n=3) and HDF
651 (mean $\pm$ SEM: 12.3 $\pm$ 0.03; n=3).

652
653 **Figure 3. Assessing pluripotency signatures of OXS8360 treated iPSC.**

654 (a) Phenotypes of iPSC treated with DMSO or OXS8360, and HDF. Expression of the pluripotency markers
655 Nanog, Tra-1-60, SSEA-3 and SSEA-4 and the fibroblast marker CD44 were measured by flow cytometry. The
656 same gate to select for live cells was applied to all conditions. Histograms show antibody stained cells (black
657 line plot) and relevant isotype control-stained cells (solid grey plot). (b) Immunocytochemistry staining
658 showing expression of pluripotency markers Nanog and Tra-1-60 in untreated and OXS8360-treated iPSC.
659 iPSC were treated over 3 passages with OXS8360 or DMSO followed by a 3 day culture without any compound
660 prior to staining. Scale bar, 100 μ m. (c) Heat map groups genes according to signatures for pluripotency and
661 trilineage differentiation for the 4 samples: (1) DMSO-treated undifferentiated, (2) OXS8360 treated for 3
662 passages undifferentiated, (3) DMSO treated then differentiated for 14 days, (4) OXS8360 treated then
663 differentiated for 14 days. Each sample is normalised to a reference set of undifferentiated samples provided
664 via the online software of the ScoreCard™ kit. Colour-coding indicates whether a gene is upregulated (red,
665 ≥ 2), downregulated (blue, <0.5) or expressed at the same level (white, ≥ 0.5 and <2). (d) Box-and-whiskers
666 plots indicate the reference signatures of undifferentiated samples as provided by the ScoreCard kit. 4
667 algorithm scores determine whether a sample is overall negative or positive for an entire differentiation or
668 pluripotency signature. Algorithm scores ≥ 2 indicate upregulation, <0.5 downregulation and scores ≥ 0.5 and
669 <2 are highly similar to a reference set of undifferentiated pluripotent stem cells. (e) Dots represent the
670 algorithm scores of the included samples for each signature: DMSO-treated undifferentiated (black),

671 OXS8360-treated undifferentiated (red), DMSO-treated and differentiated for 14 days (green), OXS8360-
672 treated and differentiated for 14 days (blue).

673

674 **Figure 4. Assessing functional pluripotency through directed differentiation.**

675 (a) Morphological phenotypes of macrophages derived from DMSO and OXS8360-treated iPSC analysed using
676 phase contrast microscopy. Shown are adherent macrophages (pMac) on day 40 of differentiation along the
677 myeloid pathway. Scale bars, 100µm. (b) Flow cytometry showing the expression of CD11b, CD14 (both
678 macrophage markers) and CD45 (pan-hematopoietic marker) at day 40 of differentiation. The same gate to
679 select for live cells was applied to each condition. Histograms in each plot represent a population stained
680 with the conjugated antibodies (black line plot) compared to its relevant isotype control (grey filled plot). (c)
681 Differentiation of OXS8360 treated iPSC into cortical neurons. Phase contrast images of DMSO and OXS8360-
682 treated iPSC on days 16 and 27. Scale bars, 50µm. (d) Immunocytochemistry staining for early neural markers
683 PAX-6 and TUJ1 in cortical neuron cultures derived from DMSO and OXS8360-treated iPSC on day 25. Scale
684 bars = 50µm.

685

686 **Figure 5. 3D static suspension culture of iPSC.**

687 Cell-aggregation assay. Single iPSC were cultured for 10 passages with or without OXS8360 in static
688 suspension culture in mTeSR and Rho-kinase inhibitor Y-27623 at a seeding density on each 4th day passage
689 of 1x10⁶ cells/mL. (a) Cell morphology on day 4 after the 10th passage (phase contrast) shows smaller
690 aggregates in presence of OXS8360 versus DMSO. Scale bar, 100µm. (b) Flow cytometry for Nanog and Tra1-
691 60 in untreated and OXS8360-treated cells at passage 10. (c) Mean cross sectional area of the aggregates was
692 determined with FIJI ImageJ. Note the formation of more homogenous aggregates in the presence of
693 OXS8360 versus DMSO as indicated by error bars. (d) Cell dissociation assay. Aggregates were centrifuged,
694 TrypLE-dissociated and resuspended in culture medium. Cell dissociation index is expressed as the percentage
695 of particles (cell clusters ≥ 4 cells) in total number of cells per well. Note the presence of fewer cell clusters

696 following iPSC culture in the presence of OXS8360. Values are mean±SEM from three independent
697 experiments. Statistical analysis was done using an unpaired t-test, ***P<0.001, ****P<0.0001.

698

699 **Figure 6 Mechanism of action of OXS8360.**

700 (a) Immunofluorescence staining for actin filaments (green), intracellular (antibody clone 36, red) and
701 extracellular E-cadherin (antibody SHE78-7, red) in DMSO and OXS8360-treated iPSC. Nuclei were
702 counterstained with Hoescht (blue). Cells were seeded overnight on μ -slides before being treated for 24h
703 with or without OXS8360. Scale bar, 100 μ m. (b) Release of soluble E-Cadherin from cultured hiPSCs under
704 OXS8360 and EDTA conditions. Monolayers of iPSC were cultured 24h prior to treatment. Statistical analysis
705 was done using a one-way ANOVA with Dunnett's multiple comparison test, ***P<0.001, ****P<0.0001, n=3.
706 (c) PKC isoform expression in iPSC line OX1-18 upon treatment with OXS8360. qRT-PCR was performed to
707 determine the relative expression levels of PKC isoforms normalised to TBP. iPSC were treated for 72h with
708 OXS8360. All PKC isoforms are expressed in both treated and untreated samples. A significant difference
709 could only be observed for the expression of PKC δ . Statistical analysis was done using a one-way ANOVA
710 with Sidak's multiple comparison test, ns P>0.05, *P<0.05, n=3. (d) Active PKC protein levels in iPSC following
711 treatment with PMA, OXS8360 and/or PKC inhibitors (C1 and Sphingosine (Sp)). Cells from PMA or OXS8360
712 treatment group alone were homogenised prior to co-treatment with PKC inhibitors. Statistical analysis was
713 done using a one-way ANOVA with Dunnett's multiple comparison test, ns P>0.05, *P<0.05, n=3. (e) Phase
714 contrast images of iPSC treated with 1 μ M OXS8360. After 24h, the medium was changed and the treatment
715 was continued either in a combinatorial approach with the PKC inhibitors Gö6976 and Gö6983 (both at 1 μ M)
716 either with OXS8360 (positive control) or medium alone (negative control). iPSC treated with OXS8360 and
717 the PKC inhibitor Gö6983 displayed colony-based morphology. Co-treatment with Gö6976 did not abrogate
718 the colony-spread phenotype. Scale bars, 100 μ m. (f) Chemical structures of PKC inhibitors Gö6976 (α , β) and
719 Gö6983 (pan-PKC) and OXS8360.

723

724

728
729